Skip Navigation


European Heart Journal Advance Access originally published online on October 28, 2008
European Heart Journal 2008 29(22):2708-2709; doi:10.1093/eurheartj/ehn450
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
29/22/2708    most recent
ehn450v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lange, R. A.
Right arrow Articles by Lindsey, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lange, R. A.
Right arrow Articles by Lindsey, M. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

HDL-cholesterol levels and cardiovascular risk: acCETPing the context

Richard A. Lange and Merry L. Lindsey*

Medicine/Cardiology, University of Texas Health Science Center, San Antonio, TX 78229, USA

* Corresponding author. Tel: +1 210 567 4673, Fax: +1 210 567 6960; Email: lindseym@uthscsa.edu

This editorial refers to ‘CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction’{dagger} by J.J. Regieli et al., on page 2792

Footnotes

The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.

The first 10% of the full text of this article appears below.

High levels of plasma high-density lipoprotein cholesterol (HDL-C) are associated with a decreased risk of cardiovascular disease. Cholesterol ester transfer protein (CETP) facilitates the transfer or cholesteryl esters from HDL to triglyceride-rich lipoproteins, and its inhibition raises HDL-C levels. Accordingly, interest has focused on CETP inhibition to augment current lipid-lowering strategies.

In a substudy from the Regression Growth Evaluation Statin Study (REGRESS) angiographic trial cohort,1 Regieli and colleagues evaluated 812 statin-treated participants and found . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction
Jakub J. Regieli, J. Wouter Jukema, Diederick E. Grobbee, John J.P. Kastelein, Jan Albert Kuivenhoven, Aeilko H. Zwinderman, Yolanda van der Graaf, Michiel L. Bots, and Pieter A. Doevendans
EHJ 2008 29: 2792-2799. [Abstract] [FREE Full Text]